zopiclone has been researched along with Chronic Insomnia in 193 studies
zopiclone: S(+)-enantiomer of racemic zopiclone; azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; was term of zopiclone 2004-2007
zopiclone : A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A total of 18 brain-injured and stroke patients, aged 20-78 yrs, were administered lorazepam, 0." | 9.11 | Comparison of lorazepam and zopiclone for insomnia in patients with stroke and brain injury: a randomized, crossover, double-blinded trial. ( Ashworth, NL; Li Pi Shan, RS, 2004) |
| "To determine the long-term efficacy of eszopiclone in patients with chronic insomnia." | 9.10 | Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. ( Amato, DA; Caron, J; Krystal, AD; Laska, E; Roth, T; Walsh, JK; Wessel, TC, 2003) |
| "A randomized, double-blind, comparative trial of zopiclone versus nitrazepam was conducted in 74 geriatric chronic insomniac patients." | 9.06 | Zopiclone versus nitrazepam: a double-blind comparative study of efficacy and tolerance in elderly patients with chronic insomnia. ( Delmotte, M; Dreyfus, JF; Klimm, HD, 1987) |
| " Clonidine is better than zopiclone for insomnia treatment in chronic pain patients." | 8.12 | Clonidine is better than zopiclone for insomnia treatment in chronic pain patients. ( Bamgbade, DO; Bamgbade, OA; Fadire, A; Mumporeze, L; Murphy-Akpieyi, O; Soni, NK; Tai-Osagbemi, J, 2022) |
| " These effects were examined independently and in combination with ethanol effects." | 6.66 | Effects of flurazepam and zopiclone on the performance of chronic insomniac patients: a study of ethanol-drug interaction. ( Buck, L; Csima, A; Mamelak, M; Price, V; Smiley, A, 1987) |
| "6 patients with chronic insomnia, ranging in age from 33 to 57, participated in the study." | 6.65 | Effects of zopiclone on the sleep of chronic insomniacs. ( Mamelak, M; Price, V; Scima, A, 1983) |
| "Tolerance or rebound insomnia was not reported." | 6.43 | Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. ( Najib, J, 2006) |
| "Both insomnia and its treatment can lead to the development of delirium in older adults." | 5.48 | Delirium associated with only one dose of zopiclone in an older adult. ( Isik, AT; Kalan, U; Soysal, P, 2018) |
| "6 patients with chronic insomnia, ranging in age from 33 to 57, participated in the study." | 5.26 | Effects of zopiclone on the sleep of chronic insomniacs. ( Mamelak, M; Price, V; Scima, A, 1982) |
| "To evaluate the safety and efficacy of eszopiclone 2 mg in elderly patients (aged 64-86 years) with chronic insomnia." | 5.12 | A polysomnography study of eszopiclone in elderly patients with insomnia. ( Erman, M; Krystal, AD; McCall, WV; Rosenberg, R; Scharf, M; Wessel, T; Zammit, GK, 2006) |
| " A total of 18 brain-injured and stroke patients, aged 20-78 yrs, were administered lorazepam, 0." | 5.11 | Comparison of lorazepam and zopiclone for insomnia in patients with stroke and brain injury: a randomized, crossover, double-blinded trial. ( Ashworth, NL; Li Pi Shan, RS, 2004) |
| "To determine the long-term efficacy of eszopiclone in patients with chronic insomnia." | 5.10 | Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. ( Amato, DA; Caron, J; Krystal, AD; Laska, E; Roth, T; Walsh, JK; Wessel, TC, 2003) |
| "A randomized, double-blind, comparative trial of zopiclone versus nitrazepam was conducted in 74 geriatric chronic insomniac patients." | 5.06 | Zopiclone versus nitrazepam: a double-blind comparative study of efficacy and tolerance in elderly patients with chronic insomnia. ( Delmotte, M; Dreyfus, JF; Klimm, HD, 1987) |
| "A double-blind study comparing zopiclone and triazolam, in 48 healthy, chronic insomniacs, was undertaken in two centers to compare the hypnotic and withdrawal effects of both compounds." | 5.06 | A comparison of the efficacy, safety and withdrawal effects of zopiclone and triazolam in the treatment of insomnia. ( Bourgouin, J; Fleming, JA; Mayes, C; McClure, DJ; Phillips, R, 1990) |
| "The launch of eszopiclone by Sepracor Inc in April 2005 in the US has marked the long-anticipated advent of a new generation of hypnotics that promise safer treatment for chronic insomnia." | 4.82 | Insomnia. ( Holzinger, E, 2005) |
| "To review the pharmacology, pharmacokinetics, efficacy data, and adverse effects of eszopiclone in the treatment of transient and chronic insomnia in adult and geriatric patients." | 4.82 | Eszopiclone for insomnia. ( Kirkwood, CK; Melton, ST; Wood, JM, 2005) |
| " Clonidine is better than zopiclone for insomnia treatment in chronic pain patients." | 4.12 | Clonidine is better than zopiclone for insomnia treatment in chronic pain patients. ( Bamgbade, DO; Bamgbade, OA; Fadire, A; Mumporeze, L; Murphy-Akpieyi, O; Soni, NK; Tai-Osagbemi, J, 2022) |
| " A 52-year-old man with a history of depression treated with escitalopram 10 mg/day, extended-release morphine 30 mg/day and zopiclone 15 mg/day was found unconscious at his home." | 3.74 | Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines. ( Baranchuk, A; Gibson, K; Methot, M; Simpson, CS; Strum, D, 2008) |
| "Its favorable adverse-effect profile and approved labeling for the treatment of chronic insomnia makes eszopiclone a viable alternative for insomnia treatment." | 3.73 | Eszopiclone. ( Halas, CJ, 2006) |
| "Insomnia is frequent in patients with advanced cancer, and a variety of pharmacological agents is used to treat this condition." | 3.11 | Zopiclone versus placebo for short-term treatment of insomnia in patients with advanced cancer-a double-blind, randomized placebo-controlled clinical multicenter phase IV trial. ( Hjermstad, MJ; Jakobsen, G; Kaasa, S; Klepstad, P; Paulsen, Ø; Sjue, K, 2022) |
| "Zolpidem was associated with drowsiness effect (odds ratio = 1." | 3.01 | Comparative efficacy of hypnotics in young and middle-aged adults with insomnia: a systematic review and network meta-analysis. ( Chen, PY; Chiu, HY; Hasan, F; Lee, HC; Romadlon, DS; Tu, YK; Wang, YH; Yuliana, LT, 2023) |
| " Only few controlled studies have characterized the effect of discontinuation of their chronic use on sleep and quality of life." | 2.90 | Withdrawal from long-term use of zopiclone, zolpidem and temazepam may improve perceived sleep and quality of life in older adults with primary insomnia. ( Kivelä, SL; Lähteenmäki, R; Neuvonen, PJ; Partinen, M; Puustinen, J; Räihä, I; Vahlberg, T, 2019) |
| "Despite the high prevalence of insomnia in patients with advanced cancer, there are no randomized controlled trials on pharmacological interventions for insomnia in this group of patients." | 2.87 | Zopiclone versus placebo for short-term treatment of insomnia in patients with advanced cancer: study protocol for a double-blind, randomized, placebo-controlled, clinical multicenter trial. ( Engstrøm, M; Fayers, P; Hjermstad, MJ; Jakobsen, G; Kaasa, S; Klepstad, P; Paulsen, Ø; Raj, SX; Sjue, K; Thronæs, M, 2018) |
| "92 outpatients (≥55 years) with primary insomnia, long-term BZDA use as hypnotics (mean duration of BZDA use 9." | 2.87 | Long-term persistence of withdrawal of temazepam, zopiclone, and zolpidem in older adults: a 3-year follow-up study. ( Aarnio, P; Kivelä, SL; Lähteenmäki, R; Neuvonen, PJ; Nurminen, J; Partinen, M; Puustinen, J; Räihä, I; Vahlberg, T, 2018) |
| "Suvorexant is a first-in-class orexin receptor antagonist for treating insomnia." | 2.82 | On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly. ( Bautmans, A; Heirman, I; Jongen, S; Laethem, T; Li, X; McCrea, J; Palcza, J; Sun, H; Troyer, MD; Van Oers, AC; Vermeeren, A; Vets, E; Vuurman, EF; Wrishko, R, 2016) |
| "The primary endpoint was the Insomnia Severity Index after four weeks of treatment." | 2.82 | Eszopiclone versus zopiclone in the treatment of insomnia. ( Bittencourt, LR; Braga, LR; Pinto, LR; Treptow, EC; Tufik, S, 2016) |
| " As impaired muscle strength and balance are risk factors for falls, we examined the effects of hypnotic withdrawal on handgrip strength and balance in older adult outpatients during and after long-term use of temazepam, zopiclone and zolpidem (here collectively referred to as "benzodiazepines")." | 2.79 | Handgrip strength and balance in older adults following withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotics. ( Kivelä, SL; Lähteenmäki, R; Lyles, A; Neuvonen, PJ; Nurminen, J; Partinen, M; Puustinen, J; Räihä, I; Vahlberg, T, 2014) |
| "To assess the effects of post-bedtime dosing with indiplon on next-day function in adults and the elderly." | 2.73 | Post-bedtime dosing with indiplon in adults and the elderly: results from two placebo-controlled, active comparator crossover studies in healthy volunteers. ( Burke, PJ; Farber, RH, 2008) |
| "Eszopiclone use was associated with a cost of $US497." | 2.73 | Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. ( Botteman, MF; Foley, DJ; Ozminkowski, RJ; Pashos, CL; Schaefer, K; Wang, S, 2007) |
| "Insomnia and major depressive disorder (MDD) may coexist." | 2.73 | Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. ( Caron, J; Fava, M; Krystal, A; McCall, WV; Roth, T; Rubens, R; Wessel, T; Wilson, P, 2007) |
| "830 primary insomnia patients who reported mean nightly total sleep time (TST) < or = 6." | 2.73 | Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. ( Amato, DA; Caron, J; Krystal, AD; Roach, J; Roth, T; Rubens, R; Schaefer, K; Wallenstein, G; Walsh, JK; Wessel, TC, 2007) |
| "Zopiclone was found to be fairly tolerated, to induce a low rate of adverse events with non-severe impact on psychomotor or cognitive performance and to produce no major harm to the overall well-being and daily living abilities." | 2.72 | Zopiclone to treat insomnia in older adults: A systematic review. ( Camargos, EF; Louzada, LL; Machado, FV; Nóbrega, OT, 2021) |
| "Insomnia is a common condition in older adults and is associated with a number of adverse medical, social, and psychological consequences." | 2.72 | Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. ( Bjorvatn, B; Havik, OE; Kvale, G; Nielsen, GH; Nordhus, IH; Omvik, S; Pallesen, S; Sivertsen, B, 2006) |
| "Eszopiclone was well tolerated in both groups; unpleasant taste was the only undesirable effect reported by >5% of patients." | 2.71 | An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. ( Krystal, A; Roehrs, TA; Roth, T; Walsh, JK; Wessel, T, 2005) |
| " Treatment was well tolerated by patients, and the most common treatment-related adverse event was unpleasant taste." | 2.71 | An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. ( Amato, D; Caron, J; Rosenberg, R; Roth, T, 2005) |
| "Eszopiclone is a new, single-isomer, non-benzodiazepine, cyclopyrrolone agent under investigation for the treatment of insomnia." | 2.71 | Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. ( Amato, DA; Caron, J; McNabb, LJ; Roth, T; Zammit, GK, 2004) |
| "Eszopiclone was well tolerated." | 2.71 | A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. ( Amato, D; Erman, M; McCall, WV; Rosenberg, R; Scharf, M; Seiden, D; Wessel, TC, 2005) |
| "Rebound effects after withdrawal from hypnotics are believed to trigger their chronic use and to enhance the risk of tolerance and dependence." | 2.70 | A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects. ( Backhaus, J; Berger, M; Feige, B; Hohagen, F; Hornyak, M; Riemann, D; Voderholzer, U, 2001) |
| "Zolpidem (ZLP), which has selective affinity to the BZ1 (omega 1) receptor and a short half-life, is a novel hypnotic." | 2.69 | The effects of zolpidem and zopiclone on daytime sleepiness and psychomotor performance. ( Isawa, S; Murasaki, M; Suzuki, M; Uchiumi, M, 2000) |
| "Thirty-two insomniac outpatients with a variety of diagnoses participated in this study." | 2.69 | Zopiclone in the treatment of insomnia: an open clinical trial. ( Disayavanish, C; Disayavanish, P; Srisurapanont, M, 1998) |
| "Twenty-four volunteers (19 women and five men) with insomnia and a history of chronic use of benzodiazepine hypnotics participated in a randomized, double blind, controlled clinical trial." | 2.69 | The effects of substituting zopiclone in withdrawal from chronic use of benzodiazepine hypnotics. ( Hacohen, D; Herer, P; Lavie, P; Pat-Horenczyk, R, 1998) |
| "Since homogeneous samples of insomniacs are difficult to recruit for pharmacotherapy studies, normal sleepers can be used to assess the protective effect of hypnotic drugs, under standardized nonconducive conditions." | 2.68 | Multidrug comparison (lorazepam, triazolam, zolpidem, and zopiclone) in situational insomnia: polysomnographic analysis by means of the cyclic alternating pattern. ( Boselli, M; Parrino, L; Smerieri, A; Spaggiari, MC; Terzano, MG, 1997) |
| " In this double-blind study in geriatric patients, drugs were administered during 3 weeks and the therapeutic effects of zopiclone at optimal dosage (5 or 7." | 2.67 | Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs. ( Bourgouin, J; Elie, R; Frenay, M; Le Morvan, P, 1990) |
| "Rebound insomnia was evident in the zopiclone group in five out of 10 items of the LSEQ." | 2.67 | A comparison of efficacy and tolerance of the short acting sedatives midazolam and zopiclone. ( Begg, EJ; Campbell, JE; Frampton, CM; Robson, RA, 1992) |
| "Sixty insomniac patients participated in a controlled double-blind parallel group study designed to investigate the dose-response relationship of zopiclone." | 2.67 | A dose-range finding study of zopiclone in insomniac patients. ( Dimitri, R; Le Morvan, P; Nair, NP; Schwartz, G; Thavundayil, JX, 1990) |
| "Zopiclone was efficacious both in patients who had not previously received hypnotic therapy (n = 37) and in patients who transferred directly to zopiclone from a benzodiazepine hypnotic (n = 26)." | 2.67 | A multi-centre open study in general practice to evaluate the efficacy and acceptability of zopiclone 7.5 mg nocte in patients requiring the prescription of an hypnotic. ( Beaumont, G; Holland, RL, 1990) |
| "Triazolam-treated patients presented significantly more day-time-interdose anxiety than zopiclone as assessed by the weekly HARS and Clinical Global Assessment of Anxiety." | 2.67 | Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety. ( Beauclair, L; Beaudry, P; Chouinard, G; Fontaine, R; Le Morvan, P, 1990) |
| "Zopiclone is an effective hypnotic comparable to temazepam." | 2.67 | A double-blind placebo-controlled trial of zopiclone 7.5 mg and temazepam 20 mg in insomnia. ( Hassan, R; Ngen, CC, 1990) |
| "Zopiclone was associated with feelings of being troubled, tense, antagonistic and bored whereas temazepam produced drowsiness, clumsiness, dreaminess and sadness." | 2.66 | Subjective effects during administration and on discontinuation of zopiclone and temazepam in normal subjects. ( Frcka, G; Lader, M, 1987) |
| "No rebound insomnia was evident during a 7 day post-treatment withdrawal period for either zopiclone or nitrazepam." | 2.66 | Zopiclone and nitrazepam: a multicenter placebo controlled comparative study of efficacy and tolerance in insomniac patients in general practice. ( Anderson, AA, 1987) |
| "Zopiclone treatment produced significantly more taste disturbance and drowsiness." | 2.66 | Zopiclone in insomniac shiftworkers. Evaluation of its hypnotic properties and its effects on mood and work performance. ( Billings, BJ; Bourgouin, J; Monchesky, TC; Phillips, R, 1989) |
| "Ninety-one insomniacs completed a four-week study of the efficacy and safety of zopiclone (Z), 7." | 2.66 | Zopiclone: a new nonbenzodiazepine hypnotic used in general practice. ( Billings, BJ; Monchesky, TC; Phillips, R, 1986) |
| "The aetiology of insomnia can be conveniently divided into six groups: physical (pain, cough, etc." | 2.66 | Insomnia in general practice: the role of temazepam and a comparison with zopiclone. ( Wheatley, D, 1986) |
| " These effects were examined independently and in combination with ethanol effects." | 2.66 | Effects of flurazepam and zopiclone on the performance of chronic insomniac patients: a study of ethanol-drug interaction. ( Buck, L; Csima, A; Mamelak, M; Price, V; Smiley, A, 1987) |
| "Some slight insomnia rebound was found with nitrazepam, but not with zopiclone." | 2.65 | Polygraphical sleep recordings in insomniac patients under zopiclone or nitrazepam. ( Dreyfus, JF; Jovanovic, UJ, 1983) |
| "Zopiclone is a useful drug for the treatment of sleep disturbances, not only because of its efficacy, but also because of its tolerability." | 2.65 | Comparative study of zopiclone and pentobarbitone as hypnotics. ( Mello de Paula, AJ, 1982) |
| "Some slight insomnia rebound was found with nitrazepam, but not with zopiclone." | 2.65 | Polygraphical sleep recordings in insomniac patients under zopiclone or nitrazepam. ( Dreyfus, JF; Jovanovic, UJ, 1982) |
| "Zopiclone was given for 14 nights to 68 geriatric patients (mean age 81 years) with sleep problems." | 2.65 | Zopiclone to geriatric patients. A parallel double-blind dose-response clinical trial of zopiclone as a hypnotic to geriatric patients - a study in a geriatric hospital. ( Börjesson, L; Dehlin, O; Ekelund, P; Gatzinska, R; Hedenrud, B; Mellström, D; Rundgren, A, 1982) |
| "Zopiclone was judged by the physicians to be superior to placebo and was preferred by the patients." | 2.65 | The acceptability of a non-benzodiazepine hypnotic (Zopiclone) in general practice. ( Chaudoir, PJ; Jarvie, NC; Wilcox, GJ, 1983) |
| "Zopiclone is a new nonbenzodiazepine hypnotic, the recommended dose of which is 7." | 2.65 | Effects of zopiclone as compared to flurazepam on sleep in women over 40 years of age. ( Buytaert, G; Hoffman, G; Quadens, OP, 1983) |
| "6 patients with chronic insomnia, ranging in age from 33 to 57, participated in the study." | 2.65 | Effects of zopiclone on the sleep of chronic insomniacs. ( Mamelak, M; Price, V; Scima, A, 1983) |
| "Zopiclone is a cyclopyrrolone derivative which exerts, in animal and man, an hypnotic activity comparable to that of flurazepam." | 2.65 | Efficacy and tolerance of zopiclone in insomniac geriatric patients. ( Deschenes, JP; Elie, R, 1983) |
| "Zopiclone is a useful drug for the treatment of sleep disturbances, not only because of its efficacy, but also because of its tolerability." | 2.65 | Comparative study of zopiclone and pentobarbitone as hypnotics. ( Mello de Paula, AJ, 1983) |
| "Zopiclone was given for 14 nights to 68 geriatric patients (mean age 81 years) with sleep problems." | 2.65 | Zopiclone to geriatric patients. A parallel double-blind dose-response clinical trial of zopiclone as a hypnotic to geriatric patients - a study in a geriatric hospital. ( Börjesson, L; Dehlin, O; Ekelund, P; Gatzinska, R; Hedenrud, B; Mellström, D; Rundgren, A, 1983) |
| " The results indicate that zopiclone is an active hypnotic compound, comparable in its effects to those of nitrazepam, the higher dosage being best adapted to the type of patients included in the study." | 2.65 | Comparison of nitrazepam and zopiclone in psychiatric patients. ( Brun, JP; Dreyfus, JF; Pull, CB, 1983) |
| "Two syndromes, hypersomnia and REM sleep behavior disorder (RBD), are increasingly recognized as harbingers of the core PD motor syndrome." | 2.48 | Sleep disorders in Parkinson's disease: many causes, few therapeutic options. ( Diederich, NJ; McIntyre, DJ, 2012) |
| "Former substance abusers and psychiatric patients appear to be at greatest risk." | 2.45 | Comparative tolerability of newer agents for insomnia. ( Zammit, G, 2009) |
| "Tolerance or rebound insomnia was not reported." | 2.43 | Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. ( Najib, J, 2006) |
| "This article will review the causes of insomnia in the elderly, the approach to patient evaluation, and the nonpharmacologic and pharmacologic treatment of insomnia." | 2.43 | Insomnia in the elderly: cause, approach, and treatment. ( Gammack, JK; Kamel, NS, 2006) |
| "Eszopiclone was well tolerated in clinical trials < or = 12 months duration, with no clinically significant evidence of pharmacological tolerance, rebound insomnia or dependence." | 2.43 | Eszopiclone for the treatment of insomnia. ( Scharf, M, 2006) |
| "Many patients with chronic insomnia, including primary insomnia and insomnia secondary to a variety of medical and psychiatric disorders, also benefit from pharmacotherapy." | 2.42 | Pharmacologic management of insomnia. ( Walsh, JK, 2004) |
| "For the symptomatic drug treatment of insomnias, the specific metabolic and pharmacokinetic, as well as possible interactions, should be considered." | 2.42 | [Drug treatment of sleep disorders in the elderly]. ( Wiegand, MH, 2003) |
| " Rifampicin significantly induced the metabolism of the newer hypnosedatives and decreased their sedative effects, indicating that a dose increase of these agents may be necessary when they are administered with rifampicin." | 2.42 | Clinically important drug interactions with zopiclone, zolpidem and zaleplon. ( Greenblatt, DJ; Hesse, LM; von Moltke, LL, 2003) |
| "The impact of insomnia on daytime functioning and its relationship with medical and psychiatric illnesses necessitate early treatment to prevent insomnia becoming persistent and to avoid the development of complications." | 2.42 | New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. ( Palomba, V; Parrino, L; Rossi, M; Smerieri, A; Terzano, MG, 2003) |
| "Patients with insomnia are characterised by excessive arousal and an inability to sleep despite reported reduced sleep hours and poor sleep quality." | 2.41 | Insomnia. Diagnosis and management. ( Grunstein, R, 2002) |
| "Zopiclone is a non-benzodiazepine hypnotic which was first reviewed in Drugs in 1986." | 2.40 | Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. ( Lamb, HM; Langtry, HD; Noble, S, 1998) |
| "Key search terms included insomnia, benzodiazepines, zolpidem, zopiclone, zaleplon, Cl 284,846, melatonin, and valerian." | 2.40 | Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. ( Hening, WA; Wagner, J; Wagner, ML, 1998) |
| "Zopiclone-treated patients reported themselves to be less impaired by daytime sedation than patients treated with the medium- and long-acting hypnosedatives flurazepam, nitrazepam and flunitrazepam." | 2.40 | A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience. ( Hajak, G, 1999) |
| "Zopiclone has been proven as a drug that favourably balances sleep induction and maintenance as well as an improvement in daytime well-being (efficacy) with a low potential for adverse effects (safety) in the symptomatic treatment of insomnia." | 2.39 | Clinical management of patients with insomnia. The role of zopiclone. ( Hajak, G; Rodenbeck, A, 1996) |
| "Rebound insomnia, reported intermittently with most of these agents, was short-lived and not clinically significant." | 2.38 | Comparative clinical profiles of triazolam versus other shorter-acting hypnotics. ( Coleman, BS; Jonas, JM; Kalinske, RW; Sheridan, AQ, 1992) |
| "Zopiclone is a new hypnotic belonging to the cyclopyrrolone chemical class." | 2.38 | Zopiclone, the third generation hypnotic: a clinical overview. ( Maillard, F; Musch, B, 1990) |
| "Eszopiclone is a zopiclone dextrorotation, which is classified as a cyclopyrrolone." | 1.62 | Case report of acute liver injury caused by the eszopiclone in a patient with chronic liver disease. ( Li, Z; Wu, T; Xin, G; Yu, G, 2021) |
| "Both insomnia and its treatment can lead to the development of delirium in older adults." | 1.48 | Delirium associated with only one dose of zopiclone in an older adult. ( Isik, AT; Kalan, U; Soysal, P, 2018) |
| "In total, 181 chronic insomnia patients were consecutively recruited." | 1.46 | Low serum 25-hydroxyvitamin D concentrations in chronic insomnia patients and the association with poor treatment outcome at 2months. ( Chen, H; He, J; Liu, Y; Luan, X; Qiu, H; Shen, H; Tu, X; Zhao, K; Zhu, Z, 2017) |
| "The aim of this study was to assess the effect of withdrawal from the long-term use of temazepam, zopiclone or zolpidem as hypnotics drugs (here referred to as BZD) on cognitive performance." | 1.40 | Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults. ( Kivelä, SL; Lähteenmäki, R; Lyles, A; Neuvonen, PJ; Partinen, M; Polo-Kantola, P; Puustinen, J; Räihä, I; Salo, P; Vahlberg, T, 2014) |
| "Gaboxadol is a selective extrasynaptic GABA(A) receptor agonist previously in development for the treatment of insomnia." | 1.35 | Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem. ( Leufkens, TR; Lund, JS; Vermeeren, A, 2009) |
| "Drugs prescribed for the treatment of insomnia can be either benzodiazepine hypnotics or the newer z-hypnotics, zopiclone and zolpidem." | 1.35 | Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. ( Bramness, JG; Engeland, A; Furu, K; Hausken, AM; Skurtveit, S, 2009) |
| "Zopiclone has the potential for being an agent of abuse and addiction." | 1.34 | Zopiclone: is it a pharmacologic agent for abuse? ( Cimolai, N, 2007) |
| "Thirty-four participants with chronic primary insomnia." | 1.33 | A comparison of actigraphy and polysomnography in older adults treated for chronic primary insomnia. ( Bjorvatn, B; Havik, OE; Nielsen, GH; Nordhus, IH; Omvik, S; Pallesen, S; Sivertsen, B; Straume, S, 2006) |
| "When insomnia is treated appropriately, compared with no treatment, patients' feelings about their quality of life are improved and, furthermore, do not appear to differ significantly from perceptions of quality of life in those without sleep-related problems." | 1.29 | Health-related quality of life in patients with insomnia treated with zopiclone. ( Leger, D; Philip, P; Quera-Salva, MA, 1996) |
| " The dosage of zopiclone prescribed at the inclusion visit was 7." | 1.28 | Postmarketing surveillance of zopiclone in insomnia: analysis of 20,513 cases. ( Allain, H; Blin, P; Decombe, R; Delahaye, C; Le Coz, F; Martinet, JP, 1991) |
| "Eleven chronic insomniacs participated in the study where both EEG sleep recordings and a subjective rating scale were used to evaluate drug effects." | 1.28 | Long term efficacy and withdrawal of zopiclone: a sleep laboratory study. ( le Morvan, P; Pecknold, J; Wilson, R, 1990) |
| "Zopiclone is a new nonbenzodiazepine hypnotic, the recommended dose of which is 7." | 1.26 | Effects of zopiclone as compared to flurazepam on sleep in women over 40 years of age. ( Buytaert, G; Hoffman, G; Quadens, OP, 1982) |
| "6 patients with chronic insomnia, ranging in age from 33 to 57, participated in the study." | 1.26 | Effects of zopiclone on the sleep of chronic insomniacs. ( Mamelak, M; Price, V; Scima, A, 1982) |
| "Zopiclone is a cyclopyrrolone derivative which exerts, in animal and man, an hypnotic activity comparable to that of flurazepam." | 1.26 | Efficacy and tolerance of zopiclone in insomniac geriatric patients. ( Deschenes, JP; Elie, R, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 34 (17.62) | 18.7374 |
| 1990's | 50 (25.91) | 18.2507 |
| 2000's | 77 (39.90) | 29.6817 |
| 2010's | 25 (12.95) | 24.3611 |
| 2020's | 7 (3.63) | 2.80 |
| Authors | Studies |
|---|---|
| Louzada, LL | 2 |
| Machado, FV | 2 |
| Quintas, JL | 1 |
| Ribeiro, GA | 1 |
| Silva, MV | 1 |
| Mendonça-Silva, DL | 1 |
| Gonçalves, BSB | 1 |
| Nóbrega, OT | 2 |
| Camargos, EF | 2 |
| Bamgbade, OA | 1 |
| Tai-Osagbemi, J | 1 |
| Bamgbade, DO | 1 |
| Murphy-Akpieyi, O | 1 |
| Fadire, A | 1 |
| Soni, NK | 1 |
| Mumporeze, L | 1 |
| Jakobsen, G | 2 |
| Sjue, K | 2 |
| Paulsen, Ø | 2 |
| Kaasa, S | 2 |
| Hjermstad, MJ | 2 |
| Klepstad, P | 2 |
| Hasan, F | 1 |
| Lee, HC | 1 |
| Chen, PY | 1 |
| Wang, YH | 1 |
| Yuliana, LT | 1 |
| Romadlon, DS | 1 |
| Tu, YK | 1 |
| Chiu, HY | 1 |
| Hermans, LWA | 1 |
| Regis, M | 1 |
| Fonseca, P | 1 |
| Overeem, S | 1 |
| Leufkens, TRM | 1 |
| Vermeeren, A | 4 |
| van Gilst, MM | 1 |
| Wu, T | 1 |
| Yu, G | 1 |
| Li, Z | 1 |
| Xin, G | 1 |
| Treves, N | 1 |
| Perlman, A | 1 |
| Kolenberg Geron, L | 1 |
| Asaly, A | 1 |
| Matok, I | 1 |
| Zhao, K | 1 |
| Luan, X | 1 |
| Liu, Y | 1 |
| Tu, X | 1 |
| Chen, H | 1 |
| Shen, H | 1 |
| Qiu, H | 1 |
| Zhu, Z | 1 |
| He, J | 1 |
| Puustinen, J | 4 |
| Lähteenmäki, R | 4 |
| Nurminen, J | 2 |
| Vahlberg, T | 4 |
| Aarnio, P | 1 |
| Partinen, M | 4 |
| Räihä, I | 4 |
| Neuvonen, PJ | 4 |
| Kivelä, SL | 4 |
| Kalan, U | 1 |
| Soysal, P | 1 |
| Isik, AT | 1 |
| Engstrøm, M | 1 |
| Raj, SX | 1 |
| Thronæs, M | 1 |
| Fayers, P | 1 |
| Crow, JM | 1 |
| Hoffmann, F | 1 |
| Polo-Kantola, P | 1 |
| Salo, P | 1 |
| Lyles, A | 2 |
| Leufkens, TR | 2 |
| Ramaekers, JG | 1 |
| de Weerd, AW | 1 |
| Riedel, WJ | 1 |
| Kapil, V | 1 |
| Green, JL | 1 |
| Le Lait, C | 1 |
| Wood, DM | 1 |
| Dargan, PI | 1 |
| Eraslan, D | 1 |
| Ertekin, E | 1 |
| Ertekin, BA | 1 |
| Oztürk, O | 1 |
| Curreen, M | 1 |
| Lidmila, J | 1 |
| Yen, CF | 1 |
| Yen, CN | 1 |
| Ko, CH | 1 |
| Hwang, TJ | 1 |
| Chen, CS | 1 |
| Chen, TT | 1 |
| Su, PW | 1 |
| Chen, ST | 1 |
| Lin, JJ | 1 |
| Zhang, YZ | 1 |
| He, HY | 1 |
| She, CM | 1 |
| Lian, J | 1 |
| Pinto, LR | 1 |
| Bittencourt, LR | 1 |
| Treptow, EC | 1 |
| Braga, LR | 1 |
| Tufik, S | 1 |
| Vets, E | 1 |
| Vuurman, EF | 1 |
| Van Oers, AC | 1 |
| Jongen, S | 1 |
| Laethem, T | 1 |
| Heirman, I | 1 |
| Bautmans, A | 1 |
| Palcza, J | 1 |
| Li, X | 1 |
| Troyer, MD | 1 |
| Wrishko, R | 1 |
| McCrea, J | 1 |
| Sun, H | 1 |
| Abba-Aji, A | 1 |
| Bardoloi, P | 1 |
| Baranchuk, A | 1 |
| Simpson, CS | 1 |
| Methot, M | 1 |
| Gibson, K | 1 |
| Strum, D | 1 |
| Hausken, AM | 1 |
| Furu, K | 1 |
| Skurtveit, S | 2 |
| Engeland, A | 2 |
| Bramness, JG | 2 |
| Lund, JS | 1 |
| Zammit, G | 1 |
| Alderman, CP | 1 |
| Gilbert, AL | 1 |
| Sivertsen, B | 4 |
| Omvik, S | 4 |
| Pallesen, S | 4 |
| Nordhus, IH | 4 |
| Bjorvatn, B | 4 |
| Mets, MA | 1 |
| Volkerts, ER | 1 |
| Olivier, B | 1 |
| Verster, JC | 1 |
| Strygin, KN | 1 |
| Morgan, K | 1 |
| Kucharczyk, E | 1 |
| Gregory, P | 1 |
| Diederich, NJ | 1 |
| McIntyre, DJ | 1 |
| Tonon, MA | 1 |
| Bonato, PS | 1 |
| Belozertsev, IuA | 1 |
| Shchelkanova, OA | 1 |
| Belozertsev, FIu | 1 |
| Iuntsev, SV | 1 |
| Grunstein, R | 1 |
| Martynov, AI | 1 |
| Veĭn, AM | 3 |
| Ostroumova, OD | 1 |
| Eligulashvili, TS | 3 |
| Mamaev, VI | 1 |
| Novinskiĭ, AA | 1 |
| Kuntze, MF | 1 |
| Bullinger, AH | 1 |
| Mueller-Spahn, F | 1 |
| Montplaisir, J | 2 |
| Hawa, R | 1 |
| Moller, H | 1 |
| Morin, C | 1 |
| Fortin, M | 1 |
| Matte, J | 1 |
| Reinish, L | 1 |
| Shapiro, CM | 2 |
| Terzano, MG | 3 |
| Rossi, M | 1 |
| Palomba, V | 1 |
| Smerieri, A | 2 |
| Parrino, L | 3 |
| Hesse, LM | 1 |
| von Moltke, LL | 1 |
| Greenblatt, DJ | 1 |
| Rudenko, AE | 1 |
| Korzhenevskiĭ, LV | 1 |
| Bashkirova, LM | 1 |
| Wiegand, MH | 3 |
| Krystal, AD | 3 |
| Walsh, JK | 4 |
| Laska, E | 1 |
| Caron, J | 7 |
| Amato, DA | 3 |
| Wessel, TC | 3 |
| Roth, T | 8 |
| Noguchi, H | 1 |
| Kitazumi, K | 1 |
| Mori, M | 1 |
| Shiba, T | 1 |
| Jacobs, GD | 1 |
| Li Pi Shan, RS | 1 |
| Ashworth, NL | 1 |
| Dündar, Y | 1 |
| Dodd, S | 1 |
| Strobl, J | 1 |
| Boland, A | 1 |
| Dickson, R | 1 |
| Walley, T | 1 |
| Sanger, DJ | 1 |
| Kramer, M | 1 |
| Vallières, A | 2 |
| Morin, CM | 3 |
| Guay, B | 2 |
| Bastien, CH | 1 |
| LeBlanc, M | 1 |
| Haasen, C | 1 |
| Mueller-Thomsen, T | 1 |
| Fink, T | 1 |
| Bussopulos, A | 1 |
| Reimer, J | 1 |
| Rosenberg, R | 3 |
| Amato, D | 3 |
| Zammit, GK | 2 |
| McNabb, LJ | 1 |
| Nutt, DJ | 1 |
| Alford, C | 1 |
| Verster, J | 1 |
| Anderson, I | 1 |
| Baldwin, D | 1 |
| Lader, M | 2 |
| Holzinger, E | 1 |
| Wessell, AM | 1 |
| Weart, CW | 1 |
| Staner, L | 1 |
| Ertlé, S | 1 |
| Boeijinga, P | 1 |
| Rinaudo, G | 1 |
| Arnal, MA | 1 |
| Muzet, A | 1 |
| Luthringer, R | 1 |
| Melton, ST | 1 |
| Wood, JM | 1 |
| Kirkwood, CK | 1 |
| Laustsen, G | 1 |
| Allain, H | 2 |
| Bentué-Ferrer, D | 1 |
| Polard, E | 1 |
| Akwa, Y | 1 |
| Patat, A | 1 |
| Krystal, A | 3 |
| Wessel, T | 4 |
| Roehrs, TA | 1 |
| Halas, CJ | 1 |
| Scharf, M | 3 |
| Erman, M | 2 |
| Seiden, D | 1 |
| McCall, WV | 4 |
| Neubauer, D | 1 |
| Fava, M | 2 |
| Rubens, R | 4 |
| Flynn, A | 1 |
| Cox, D | 1 |
| Najib, J | 1 |
| Kamel, NS | 1 |
| Gammack, JK | 1 |
| Havik, OE | 3 |
| Kvale, G | 1 |
| Nielsen, GH | 2 |
| Antai-Otong, D | 1 |
| Straume, S | 1 |
| Lesser, GT | 1 |
| Persaud, R | 1 |
| Soares, CN | 1 |
| Joffe, H | 1 |
| Cohen, L | 1 |
| Capua, T | 1 |
| Terao, A | 1 |
| Miyamoto, M | 1 |
| Botteman, MF | 1 |
| Ozminkowski, RJ | 1 |
| Wang, S | 1 |
| Pashos, CL | 1 |
| Schaefer, K | 2 |
| Foley, DJ | 1 |
| Wilson, P | 1 |
| Roach, J | 1 |
| Wallenstein, G | 1 |
| Cranwell-Bruce, LA | 1 |
| Bloetzer, C | 1 |
| Carota, A | 1 |
| Augsburger, M | 1 |
| Despland, PA | 1 |
| Rossetti, AO | 1 |
| Cimolai, N | 1 |
| Bachmann, CS | 1 |
| Berg, EA | 1 |
| Spigset, O | 1 |
| Slørdal, L | 1 |
| Gustavsen, I | 1 |
| Neutel, I | 1 |
| Mørland, J | 1 |
| Farber, RH | 1 |
| Burke, PJ | 1 |
| Belleville, G | 1 |
| Siriwardena, AN | 1 |
| Qureshi, MZ | 1 |
| Dyas, JV | 1 |
| Middleton, H | 1 |
| Orner, R | 1 |
| Chaudoir, PJ | 2 |
| Jarvie, NC | 1 |
| Wilcox, GJ | 1 |
| Quadens, OP | 2 |
| Hoffman, G | 2 |
| Buytaert, G | 2 |
| Mamelak, M | 3 |
| Scima, A | 2 |
| Price, V | 3 |
| Wickstrøm, E | 2 |
| Barbo, SE | 2 |
| Dreyfus, JF | 6 |
| Jerkø, D | 2 |
| Kleiven, R | 2 |
| Slåttbrekk, R | 2 |
| Stray Tønnesen, JN | 2 |
| Elie, R | 4 |
| Deschenes, JP | 2 |
| Mello de Paula, AJ | 2 |
| Dehlin, O | 4 |
| Rundgren, A | 3 |
| Börjesson, L | 2 |
| Ekelund, P | 2 |
| Gatzinska, R | 2 |
| Hedenrud, B | 2 |
| Mellström, D | 2 |
| Pull, CB | 1 |
| Brun, JP | 1 |
| Jovanovic, UJ | 2 |
| Giercksky, KE | 1 |
| Wickstrom, E | 1 |
| Jobert, M | 3 |
| Poiseau, E | 3 |
| Jähnig, P | 3 |
| Gaillard, P | 1 |
| Schulz, H | 3 |
| Hajak, G | 5 |
| Clarenbach, P | 2 |
| Fischer, W | 4 |
| Haase, W | 1 |
| Rüther, E | 3 |
| Mahendran, R | 1 |
| Chee, KT | 1 |
| Peh, LH | 1 |
| Wong, KE | 1 |
| Lim, L | 1 |
| Levin, IaI | 2 |
| Posokhov, SI | 2 |
| Kovrov, GV | 2 |
| Bashmakov, MIu | 1 |
| Rubin, B | 2 |
| Fava, GA | 1 |
| Bozin-Juracić, J | 1 |
| Boselli, M | 1 |
| Spaggiari, MC | 1 |
| Gasanov, RL | 1 |
| Poluéktov, MG | 1 |
| Bengtsson, C | 1 |
| Pallavicini, J | 1 |
| Acevedo, X | 1 |
| Noble, S | 1 |
| Langtry, HD | 1 |
| Lamb, HM | 1 |
| Katsunuma, H | 1 |
| Shimizu, T | 1 |
| Ogawa, K | 1 |
| Kubo, H | 1 |
| Ishida, H | 1 |
| Yoshihama, A | 1 |
| Wagner, J | 1 |
| Wagner, ML | 1 |
| Hening, WA | 1 |
| Disayavanish, C | 1 |
| Srisurapanont, M | 1 |
| Disayavanish, P | 1 |
| Rodenbeck, A | 2 |
| Bandelow, B | 1 |
| Broocks, A | 1 |
| Pat-Horenczyk, R | 1 |
| Hacohen, D | 1 |
| Herer, P | 1 |
| Lavie, P | 1 |
| Leger, D | 1 |
| Quera-Salva, MA | 1 |
| Philip, P | 1 |
| Diav-Citrin, O | 1 |
| Okotore, B | 1 |
| Lucarelli, K | 1 |
| Koren, G | 1 |
| Uchiumi, M | 1 |
| Isawa, S | 1 |
| Suzuki, M | 1 |
| Murasaki, M | 1 |
| Roszinsky-Köcher, G | 2 |
| Schwalb, B | 2 |
| Eckert, MW | 2 |
| Voderholzer, U | 1 |
| Riemann, D | 1 |
| Hornyak, M | 1 |
| Backhaus, J | 1 |
| Feige, B | 1 |
| Berger, M | 1 |
| Hohagen, F | 1 |
| Begg, EJ | 1 |
| Robson, RA | 1 |
| Frampton, CM | 1 |
| Campbell, JE | 1 |
| Kubicki, S | 3 |
| Jonas, JM | 1 |
| Coleman, BS | 1 |
| Sheridan, AQ | 1 |
| Kalinske, RW | 1 |
| Kajaste, S | 1 |
| Palomäki, H | 1 |
| Spieweg, I | 1 |
| Sanders, S | 1 |
| Kamphuisen, HA | 1 |
| van Dam, JG | 1 |
| Delahaye, C | 2 |
| Le Coz, F | 1 |
| Blin, P | 1 |
| Decombe, R | 1 |
| Martinet, JP | 1 |
| Wheatley, D | 3 |
| Kelly, F | 1 |
| O'Grady, J | 1 |
| Champey, Y | 1 |
| Lavoie, G | 1 |
| Bourgouin, J | 6 |
| Le Morvan, P | 5 |
| Pecknold, J | 1 |
| Wilson, R | 1 |
| Nair, NP | 1 |
| Schwartz, G | 1 |
| Dimitri, R | 1 |
| Thavundayil, JX | 1 |
| Beaumont, G | 1 |
| Holland, RL | 2 |
| Ferrand, B | 1 |
| Pieddeloup, C | 1 |
| Musch, B | 3 |
| Maillard, F | 3 |
| Bodkin, NL | 1 |
| O'Donnell, J | 1 |
| Anderson, A | 1 |
| Fleming, JA | 2 |
| McClure, DJ | 1 |
| Mayes, C | 1 |
| Phillips, R | 3 |
| Frenay, M | 1 |
| Mouret, J | 1 |
| Ruel, D | 1 |
| Bianchi, M | 2 |
| Ponciano, E | 1 |
| Freitas, F | 1 |
| Camara, J | 1 |
| Faria, M | 1 |
| Barreto, M | 1 |
| Hindmarch, I | 1 |
| Ngen, CC | 1 |
| Hassan, R | 1 |
| Fontaine, R | 1 |
| Beaudry, P | 1 |
| Beauclair, L | 1 |
| Chouinard, G | 1 |
| Rendle, MA | 1 |
| Bergener, M | 1 |
| Gola, R | 1 |
| Hesse, C | 1 |
| Syvälahti, E | 1 |
| Monchesky, TC | 2 |
| Billings, BJ | 2 |
| Agnoli, A | 1 |
| Manna, V | 1 |
| Martucci, N | 1 |
| Frcka, G | 1 |
| Anderson, AA | 1 |
| Tamminen, T | 1 |
| Hansen, PP | 1 |
| Klimm, HD | 1 |
| Delmotte, M | 1 |
| Hamilton, P | 1 |
| Buck, L | 1 |
| Csima, A | 1 |
| Smiley, A | 1 |
| Autret, E | 1 |
| Autret, A | 1 |
| Gélinas, B | 1 |
| Thorsteinson, L | 1 |
| Lapierre, YD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Z-Drugs for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomized, Triple-blind, Placebo-controlled Study[NCT03075241] | Phase 3 | 62 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| Lemborexant vs Zopiclone vs Clonidine for Insomnia Treatment in Chronic Pain Patients[NCT05618002] | 150 participants (Anticipated) | Observational | 2022-11-08 | Recruiting | |||
| Pharmacological Treatment of Insomnia in Palliative Care: A Randomized, Double-blind, Placebo Controlled, Parallel-group, Multicenter Trial Investigating the Short Time Effect of Zopiclone on Self-reported Sleep Quality in Patients With Advanced Cancer Wh[NCT02807922] | Phase 4 | 43 participants (Actual) | Interventional | 2016-11-15 | Completed | ||
| Development of a Coordinated, Community-Based Medication Management Model for Home-Dwelling Aged in Primary Care[NCT02545257] | 191 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| Addressing Nocturnal Sleep/Wake Effects on Risk of Suicide in Older Adults (ANSWERS-OA): A Pilot, Open-Label, Randomized Controlled Trial of Digital Cognitive Behavioral Therapy for Insomnia[NCT04986007] | 70 participants (Anticipated) | Interventional | 2021-09-01 | Enrolling by invitation | |||
| [NCT05753943] | 0 participants | Expanded Access | No longer available | ||||
| A Phase III, Non-inferiority, Double-blind, Unicenter Clinical Trial With Two Treatment Arms - Test Group With Eszopiclone 3 mg Versus Zopiclone 7.5 mg - for the Treatment of Insomnia[NCT01100164] | Phase 3 | 263 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Double-blind, Placebo-controlled Study of the Safety and Efficacy of Eszopiclone in the Treatment of Insomnia in Patients With Chronic Low Back Pain[NCT00365976] | Phase 4 | 58 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Treatment of High-altitude Sleep Disturbance: A Double-blind Comparison of Temazepam Versus Acetazolamide.[NCT01519544] | 34 participants (Actual) | Interventional | 2012-03-31 | Completed | |||
| Web-based Cognitive Behavioral Treatment for Insomnia in Dementia Caregivers[NCT04632628] | 60 participants (Anticipated) | Interventional | 2022-01-01 | Recruiting | |||
| Evaluation of the Benefits of Individualized Advice Administration on Quality of Sleep for the Elderly Living at Home Prospective, Monocentric and Open Study[NCT03594851] | 45 participants (Actual) | Interventional | 2018-01-08 | Completed | |||
| [NCT00295386] | Phase 4 | 0 participants | Interventional | 2004-01-31 | Completed | ||
| Nightly Light Exposure in Pregnancy: Blue-blocking Glasses as an Intervention to Ease Sleep Disturbances and to Improve Mood[NCT03114072] | 60 participants (Anticipated) | Interventional | 2017-06-06 | Active, not recruiting | |||
| The Efficacy of Eszopiclone 3 mg Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause or Menopause[NCT00366093] | Phase 3 | 410 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| Pilot Study to Assess Tolerability and Preliminary Efficacy of a Titrated Dose of Gabapentin up to 600mg Administered at Bedtime for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women With VMS.[NCT02040532] | 32 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe. (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 6.45 | 6.38 | 4.54 | 4.14 | 2.62 |
| Placebo | 7.10 | 6.57 | 5.53 | 5.07 | 6.21 |
The ISI is a seven-item self-report questionnaire that provides a global measure of insomnia severity based on difficulty falling or staying asleep, satisfaction with sleep, or degree of impairment with daytime functioning. The total score ranges from 0-28: 0-7 (no clinical insomnia), 8-14 (subthreshold insomnia), 15-21 (insomnia of moderate severity), and 22-28 (severe insomnia). (NCT00365976)
Timeframe: Prenaprosyn Baseline, Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Prenaprosyn Baseline | Postnaprosyn baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 18.85 | 18.00 | 11.28 | 10.61 | 8.38 |
| Placebo | 20.26 | 16.78 | 12.85 | 12.74 | 13.75 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | minutes (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 38.28 | 22.36 | 17.50 | 15.28 |
| Placebo | 34.11 | 27.00 | 23.10 | 19.91 |
Nightly total sleep time was averaged from diary entries. (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, week 2, week 4
| Intervention | Minutes (Mean) | |||
|---|---|---|---|---|
| postnaprosyn baseline | week 1 | week 2 | Week 4 | |
| Eszopiclone | 316.96 | 403.47 | 421.97 | 411.97 |
| Placebo | 380.45 | 375.56 | 382.11 | 388.96 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | awakenings (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 2.29 | 1.31 | 1.35 | 1.33 |
| Placebo | 2.08 | 1.98 | 2.13 | 2.34 |
Pain ratings included a global impression of pain rating (PGI) (1-5 rating with 1 being little pain and 5 is worst pain) (NCT00365976)
Timeframe: postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 4.02 | 3.54 | 3.30 | 3.08 |
| Placebo | 3.90 | 3.82 | 4.01 | 3.80 |
"The Roland-Morris Low Back Pain Disability Questionnaire (RMLBPDQ) is a 24-item instrument that assesses the extent to which activities of daily living are affected by LBP. It is composed of 24 yes-no items assessing potential disabilities.~Scores range from 0 (no disability) to 24 (severe disability)." (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 12.27 | 9.97 | 9.10 | 7.63 | 6.59 |
| Placebo | 11.33 | 10.30 | 9.05 | 9.32 | 7.94 |
Sleep quality ratings are based on a 1-10 Likert scale. Low scores represent poorer sleep quality and higher scores represent better quality sleep (NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 4.52 | 5.99 | 6.18 | 6.38 |
| Placebo | 4.44 | 4.90 | 5.33 | 5.29 |
Scores are measured on a 100 mm Visual Analog Scale (VAS). The VAS scale ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, Week 2, Week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 48.51 | 40.72 | 34.70 | 31.69 |
| Placebo | 53.79 | 51.99 | 51.25 | 51.60 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | minutes (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 91.51 | 49.34 | 37.07 | 36.74 |
| Placebo | 81.43 | 76.71 | 81.32 | 76.18 |
"The Quality of life-Menopause specific is assessed by the Menopause Specific Quality of Life (MENQOL).~The MENQOL is self-administered and consists of a total of 29 items in a Likert-scale format. Each item assesses the impact of one of four domains of menopausal symptoms, as experienced over the last month: vasomotor (items 1-3), psychosocial (items 4-10), physical (items 11-26), and sexual (items 27-29). Items pertaining to a specific symptom are rated as present or not present, and if present, how bothersome on a zero (not bothersome) to six (extremely bothersome) scale. Means are computed for each subscale by dividing the sum of the domain's items by the number of items within that domain. Non-endorsement of an item is scored a 1 and endorsement a 2, plus the number of the particular rating, so that the possible score on any item ranges from 1-8. Total score also ranges from 1-8." (NCT02040532)
Timeframe: Baseline, study completion at 7 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| MENQOL scores at baseline | MENQOL scores at study completion | |
| Open-label Gabapentin | 3.2 | 1.9 |
Quality of life-Overall was assessed with the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). The Q-LES-Q is a 16-item self-report questionnaire that assesses enjoyment of and satisfaction with life. The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score. The last two items are not included in the total score but are standalone items. The raw total score ranges from 14 to 70 with higher scores indicating higher quality of life enjoyment and satisfaction. (NCT02040532)
Timeframe: Baseline, study completion at 7 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Q-LES-Q scores at baseline | Q-LES-Q scores at study completion | |
| Open-label Gabapentin | 60.3 | 61.7 |
"Severity of insomnia was measured throughout the study using the Insomnia Severity Index (ISI) .The ISI is a 7-item scale that evaluates the severity of insomnia retrospectively over the past week. The scale is more specific to insomnia symptoms than the Pittsburgh scale (PSQI), which focuses more broadly on overall sleep quality.~The ISI score ranges from a minimum of 0 to 28. A score of 0-7=no clinically significant insomnia, 8-14=subthreshold insomnia, 5-21=clinical insomnia (moderate severity), 22-28=clinical insomnia (severe), with higher values indicating more severe insomnia." (NCT02040532)
Timeframe: Baseline, study completion at 7 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| mean ISI score at baseline | mean ISI score at study completion | |
| Open-label Gabapentin | 15.6 | 6.0 |
"Sleep quality and disturbances during the past month were assessed with the Pittsburgh Sleep Quality Index (PSQI). The PSQI also incorporates daytime functioning into the total score.~In scoring the PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality." (NCT02040532)
Timeframe: Baseline, study completion at 7 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| PSQI total score at baseline | PSQI total score at study completion | |
| Open-label Gabapentin | 9.6 | 4.9 |
Vasomotor symptoms (VMS) were tracked and quantified prospectively using a daily hot flash diary. The hot flash diary was adapted from a 7-day self-report tool for vasomotor symptoms originally developed by the North Central Cancer Treatment Group (NCCTG). The diary asks for the subject to log number of hot flashes during the day and night, severity of hot flashes during day and night, and how bothersome the hot flashes were during day and night. Vasomotor symptoms were also systematically assessed at baseline, week 4, and week 7 using the Hot Flash-Related Daily Interference Scale (HFRDIS), a 10-item self-report questionnaire to determine perceived hot flash interference with quality of life and daily activities. (NCT02040532)
Timeframe: Baseline, study completion at 7 weeks
| Intervention | vasomotor symptoms (VMS) per day (Mean) | |
|---|---|---|
| mean VMS per day at baseline | mean VMS per day at study completion | |
| Open-label Gabapentin | 4.1 | 2.2 |
Vasomotor symptoms (VMS) were tracked and quantified prospectively using a daily hot flash diary. The hot flash diary was adapted from a 7-day self-report tool for vasomotor symptoms originally developed by the North Central Cancer Treatment Group (NCCTG). The diary asks for the subject to log number of hot flashes during the day and night, severity of hot flashes during day and night, and how bothersome the hot flashes were during day and night. Vasomotor symptoms were also systematically assessed at baseline, week 4, and week 7 using the Hot Flash-Related Daily Interference Scale (HFRDIS), a 10-item self-report questionnaire to determine perceived hot flash interference with quality of life and daily activities. (NCT02040532)
Timeframe: Baseline, study completion at 7 weeks
| Intervention | vasomotor symptoms (VMS) per night (Mean) | |
|---|---|---|
| mean VMS per night at baseline | mean VMS per night at study completion | |
| Open-label Gabapentin | 3.5 | 1.1 |
39 reviews available for zopiclone and Chronic Insomnia
| Article | Year |
|---|---|
Comparative efficacy of hypnotics in young and middle-aged adults with insomnia: a systematic review and network meta-analysis.
Topics: Adolescent; Adult; Aged; Humans; Hypnotics and Sedatives; Middle Aged; Network Meta-Analysis; Sleep | 2023 |
Zopiclone to treat insomnia in older adults: A systematic review.
Topics: Aged; Azabicyclo Compounds; Cross-Sectional Studies; Humans; Hypnotics and Sedatives; Piperazines; S | 2021 |
Z-drugs and risk for falls and fractures in older adults-a systematic review and meta-analysis.
Topics: Accidental Falls; Acetamides; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Azabicyclo Compoun | 2018 |
Zopiclone: Is there cause for concern in addiction services and general practice?
Topics: Accidents, Traffic; Automobile Driving; Azabicyclo Compounds; General Practice; Humans; Hypnotics an | 2014 |
[Research Progress on Forensic Toxicology of Z-drugs].
Topics: Acetamides; Azabicyclo Compounds; Drug Overdose; Forensic Medicine; Forensic Toxicology; Humans; Hyp | 2015 |
Comparative tolerability of newer agents for insomnia.
Topics: Azabicyclo Compounds; Clinical Trials as Topic; Drug Interactions; Humans; Hypnotics and Sedatives; | 2009 |
[Sleep and stress].
Topics: Adaptation, Psychological; Animals; Azabicyclo Compounds; Circadian Rhythm; Humans; Piperazines; Pol | 2011 |
Sleep disorders in Parkinson's disease: many causes, few therapeutic options.
Topics: Azabicyclo Compounds; Disorders of Excessive Somnolence; Humans; Hypnotics and Sedatives; Parkinson | 2012 |
Methods for the analysis of nonbenzodiazepine hypnotic drugs in biological matrices.
Topics: Acetamides; Azabicyclo Compounds; Chromatography, High Pressure Liquid; Electrophoresis, Capillary; | 2012 |
Insomnia. Diagnosis and management.
Topics: Anti-Anxiety Agents; Azabicyclo Compounds; Cognitive Behavioral Therapy; Humans; Hypnotics and Sedat | 2002 |
Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement.
Topics: Acetamides; Anti-Anxiety Agents; Azabicyclo Compounds; Benzodiazepines; Canada; Consensus; Drug Inte | 2003 |
New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon.
Topics: Acetamides; Animals; Azabicyclo Compounds; Clinical Trials as Topic; Humans; Piperazines; Pyridines; | 2003 |
Clinically important drug interactions with zopiclone, zolpidem and zaleplon.
Topics: Acetamides; Antidepressive Agents; Antipsychotic Agents; Azabicyclo Compounds; Drug Interactions; Hi | 2003 |
[Drug treatment of sleep disorders in the elderly].
Topics: Acetamides; Aged; Aged, 80 and over; Antidepressive Agents; Antipsychotic Agents; Azabicyclo Compoun | 2003 |
Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis.
Topics: Acetamides; Azabicyclo Compounds; Benzodiazepines; Humans; Hypnotics and Sedatives; Piperazines; Pyr | 2004 |
The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents.
Topics: Acetamides; Animals; Azabicyclo Compounds; GABA-A Receptor Agonists; Humans; Hypnotics and Sedatives | 2004 |
Pharmacologic management of insomnia.
Topics: Antidepressive Agents; Azabicyclo Compounds; Benzodiazepines; Clinical Trials as Topic; GABA-A Recep | 2004 |
Insomnia.
Topics: Azabicyclo Compounds; Clinical Trials as Topic; Humans; Hypnotics and Sedatives; Molecular Structure | 2005 |
Eszopiclone for insomnia.
Topics: Azabicyclo Compounds; Chronic Disease; Clinical Trials as Topic; Humans; Hypnotics and Sedatives; ME | 2005 |
Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review.
Topics: Accidental Falls; Acetamides; Aged; Aged, 80 and over; Azabicyclo Compounds; Benzodiazepines; Case-C | 2005 |
Eszopiclone for the treatment of insomnia.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Animals; Azabicyclo Compounds; Dose-Response Relationsh | 2006 |
Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia.
Topics: Azabicyclo Compounds; Chronic Disease; Humans; Hypnotics and Sedatives; Piperazines; Sleep Initiatio | 2006 |
Insomnia in the elderly: cause, approach, and treatment.
Topics: Acetamides; Aged; Aging; Antidepressive Agents; Azabicyclo Compounds; Behavior Therapy; Benzodiazepi | 2006 |
The art of prescribing. Risks and benefits of non-benzodiazepine receptor agonists in the treatment of acute primary insomnia in older adults.
Topics: Acetamides; Acute Disease; Azabicyclo Compounds; Benzodiazepines; Causality; Drug Prescriptions; GAB | 2006 |
[Recent and potential drugs for treatment of insomnia].
Topics: Animals; Azabicyclo Compounds; Benzodiazepines; Diphenhydramine; Drug Design; Fluorobenzenes; GABA-A | 2007 |
Hypnotic sedative drugs.
Topics: Acetamides; Azabicyclo Compounds; Chemistry, Pharmaceutical; Cost of Illness; Humans; Hypnotics and | 2007 |
[New non-benzodiazepine hypnotics. Progress in therapy of sleep disorders?].
Topics: Anti-Anxiety Agents; Azabicyclo Compounds; Benzodiazepines; Humans; Hypnotics and Sedatives; Piperaz | 1995 |
Polysomnographic effects of hypnotic drugs. A review.
Topics: Adult; Anti-Anxiety Agents; Azabicyclo Compounds; Benzodiazepines; Humans; Hypnotics and Sedatives; | 1996 |
Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia.
Topics: Azabicyclo Compounds; Benzodiazepines; Clinical Trials as Topic; Humans; Hypnotics and Sedatives; Pi | 1998 |
Treatment of insomnia by concomitant therapy with Zopiclone and Aniracetam in patients with cerebral infarction, cerebroatrophy, Alzheimer's disease and Parkinson's disease.
Topics: Aged; Alzheimer Disease; Atrophy; Azabicyclo Compounds; Cerebral Cortex; Cerebral Infarction; Drug T | 1998 |
Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia.
Topics: Acetamides; Azabicyclo Compounds; Benzodiazepines; Clinical Protocols; Humans; Hypnotics and Sedativ | 1998 |
Clinical management of patients with insomnia. The role of zopiclone.
Topics: Azabicyclo Compounds; Combined Modality Therapy; Humans; Hypnotics and Sedatives; Piperazines; Psych | 1996 |
A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience.
Topics: Animals; Azabicyclo Compounds; Benzodiazepines; Clinical Trials as Topic; Humans; Hypnotics and Seda | 1999 |
Comparative clinical profiles of triazolam versus other shorter-acting hypnotics.
Topics: Azabicyclo Compounds; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Hypnotics | 1992 |
[Advantages and disadvantages of sleeping pills].
Topics: Azabicyclo Compounds; Benzodiazepines; Humans; Hypnotics and Sedatives; Piperazines; Sleep Initiatio | 1991 |
[Sleeping poorly due to sedatives (rebound insomnia), and the role of zopiclone].
Topics: Azabicyclo Compounds; Benzodiazepines; Humans; Hypnotics and Sedatives; Piperazines; Sleep Initiatio | 1992 |
Zopiclone: another carriage on the tranquilliser train.
Topics: Azabicyclo Compounds; Humans; Hypnotics and Sedatives; Piperazines; Sleep Initiation and Maintenance | 1990 |
Zopiclone, the third generation hypnotic: a clinical overview.
Topics: Azabicyclo Compounds; Dose-Response Relationship, Drug; Electroencephalography; Humans; Hypnotics an | 1990 |
[Management of insomnia].
Topics: Anti-Anxiety Agents; Azabicyclo Compounds; Benzodiazepines; Humans; Hypnotics and Sedatives; Piperaz | 1989 |
84 trials available for zopiclone and Chronic Insomnia
| Article | Year |
|---|---|
The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer's disease: a randomized, triple-blind, placebo-controlled trial.
Topics: Aged, 80 and over; Alzheimer Disease; Azabicyclo Compounds; Double-Blind Method; Humans; Hypnotics a | 2022 |
Zopiclone versus placebo for short-term treatment of insomnia in patients with advanced cancer-a double-blind, randomized placebo-controlled clinical multicenter phase IV trial.
Topics: Adult; Aged; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Male; Neoplasms; Piperazi | 2022 |
Long-term persistence of withdrawal of temazepam, zopiclone, and zolpidem in older adults: a 3-year follow-up study.
Topics: Aged; Azabicyclo Compounds; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypnotics and Se | 2018 |
Withdrawal from long-term use of zopiclone, zolpidem and temazepam may improve perceived sleep and quality of life in older adults with primary insomnia.
Topics: Aged; Aged, 80 and over; Azabicyclo Compounds; Double-Blind Method; Female; Humans; Hypnotics and Se | 2019 |
Zopiclone versus placebo for short-term treatment of insomnia in patients with advanced cancer: study protocol for a double-blind, randomized, placebo-controlled, clinical multicenter trial.
Topics: Azabicyclo Compounds; Clinical Trials, Phase IV as Topic; Double-Blind Method; Drug Administration S | 2018 |
Residual effects of zopiclone 7.5 mg on highway driving performance in insomnia patients and healthy controls: a placebo controlled crossover study.
Topics: Administration, Oral; Adult; Aged; Automobile Driving; Azabicyclo Compounds; Case-Control Studies; C | 2014 |
Treatment of insomnia with hypnotics resulting in improved sexual functioning in post-menopausal women.
Topics: Azabicyclo Compounds; Female; Humans; Hypnotics and Sedatives; Piperazines; Postmenopause; Selective | 2014 |
Handgrip strength and balance in older adults following withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotics.
Topics: Aged; Aged, 80 and over; Azabicyclo Compounds; Female; Follow-Up Studies; Hand Strength; Humans; Hyp | 2014 |
Eszopiclone versus zopiclone in the treatment of insomnia.
Topics: Adult; Azabicyclo Compounds; Double-Blind Method; Dysgeusia; Eszopiclone; Female; Headache; Humans; | 2016 |
On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly.
Topics: Aged; Aged, 80 and over; Automobile Driving; Azabicyclo Compounds; Azepines; Cross-Over Studies; Dos | 2016 |
[A new approach to the treatment of sleep disorders in patients with cerebrovascular diseases].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Azabicyclo Compounds; Cerebrovascular Disorder | 2003 |
Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.
Topics: Adult; Aged; Azabicyclo Compounds; Chronic Disease; Circadian Rhythm; Double-Blind Method; Female; H | 2003 |
Comparison of lorazepam and zopiclone for insomnia in patients with stroke and brain injury: a randomized, crossover, double-blinded trial.
Topics: Administration, Oral; Adult; Aged; Attitude to Health; Azabicyclo Compounds; Brain Injuries; Cogniti | 2004 |
Sequential treatment for chronic insomnia: a pilot study.
Topics: Adult; Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therap | 2004 |
An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults.
Topics: Adult; Azabicyclo Compounds; Circadian Rhythm; Double-Blind Method; Female; Humans; Intelligence; In | 2005 |
Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia.
Topics: Administration, Oral; Adult; Azabicyclo Compounds; Double-Blind Method; Drug Administration Schedule | 2004 |
Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia.
Topics: Administration, Oral; Adult; Azabicyclo Compounds; Double-Blind Method; Drug Administration Schedule | 2004 |
Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia.
Topics: Administration, Oral; Adult; Azabicyclo Compounds; Double-Blind Method; Drug Administration Schedule | 2004 |
Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia.
Topics: Administration, Oral; Adult; Azabicyclo Compounds; Double-Blind Method; Drug Administration Schedule | 2004 |
Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring.
Topics: Adult; Arousal; Automobile Driving; Azabicyclo Compounds; Circadian Rhythm; Computer Simulation; Dia | 2005 |
An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia.
Topics: Adult; Aged; Azabicyclo Compounds; Cross-Over Studies; Drug Administration Schedule; Female; Follow- | 2005 |
Sequential combinations of drug and cognitive behavioral therapy for chronic insomnia: an exploratory study.
Topics: Adult; Azabicyclo Compounds; Behavior Therapy; Chronic Disease; Cognitive Behavioral Therapy; Combin | 2005 |
A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia.
Topics: Aged; Azabicyclo Compounds; Body Mass Index; Double-Blind Method; Drug Tolerance; Female; Humans; Hy | 2005 |
Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Depressive Disorder; Double-B | 2006 |
Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial.
Topics: Aged; Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Double-Blind Method; Fema | 2006 |
A polysomnography study of eszopiclone in elderly patients with insomnia.
Topics: Aged; Aged, 80 and over; Azabicyclo Compounds; Double-Blind Method; Female; Humans; Hypnotics and Se | 2006 |
Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial.
Topics: Affect; Azabicyclo Compounds; Double-Blind Method; Female; Hot Flashes; Humans; Hypnotics and Sedati | 2006 |
Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial.
Topics: Affect; Azabicyclo Compounds; Double-Blind Method; Female; Hot Flashes; Humans; Hypnotics and Sedati | 2006 |
Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial.
Topics: Affect; Azabicyclo Compounds; Double-Blind Method; Female; Hot Flashes; Humans; Hypnotics and Sedati | 2006 |
Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial.
Topics: Affect; Azabicyclo Compounds; Double-Blind Method; Female; Hot Flashes; Humans; Hypnotics and Sedati | 2006 |
Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model.
Topics: Adult; Aged; Azabicyclo Compounds; Costs and Cost Analysis; Female; Humans; Hypnotics and Sedatives; | 2007 |
Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression.
Topics: Adult; Azabicyclo Compounds; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Drug Admi | 2007 |
Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations.
Topics: Adult; Arousal; Azabicyclo Compounds; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; | 2007 |
Post-bedtime dosing with indiplon in adults and the elderly: results from two placebo-controlled, active comparator crossover studies in healthy volunteers.
Topics: Adult; Aged; Aged, 80 and over; Azabicyclo Compounds; Benzodiazepines; Cross-Over Studies; Double-Bl | 2008 |
Hypnotic discontinuation in chronic insomnia: impact of psychological distress, readiness to change, and self-efficacy.
Topics: Acetamides; Adaptation, Psychological; Adult; Aged; Anxiety; Attitude to Health; Azabicyclo Compound | 2008 |
Daytime functioning in older patients suffering from chronic insomnia: treatment outcome in a randomized controlled trial comparing CBT with Zopiclone.
Topics: Aged; Azabicyclo Compounds; Cognitive Behavioral Therapy; Female; Humans; Hypnotics and Sedatives; M | 2008 |
The acceptability of a non-benzodiazepine hypnotic (Zopiclone) in general practice.
Topics: Adult; Aged; Azabicyclo Compounds; Clinical Trials as Topic; Double-Blind Method; Family Practice; F | 1983 |
Effects of zopiclone as compared to flurazepam on sleep in women over 40 years of age.
Topics: Azabicyclo Compounds; Clinical Trials as Topic; Double-Blind Method; Electroencephalography; Electro | 1983 |
Effects of zopiclone on the sleep of chronic insomniacs.
Topics: Adult; Azabicyclo Compounds; Chronic Disease; Clinical Trials as Topic; Electroencephalography; Fema | 1983 |
A comparative study of zopiclone and flunitrazepam in insomniacs seen by general practitioners.
Topics: Adolescent; Adult; Azabicyclo Compounds; Clinical Trials as Topic; Double-Blind Method; Family Pract | 1983 |
Efficacy and tolerance of zopiclone in insomniac geriatric patients.
Topics: Aged; Azabicyclo Compounds; Clinical Trials as Topic; Female; Flunitrazepam; Humans; Hypnotics and S | 1983 |
Comparative study of zopiclone and pentobarbitone as hypnotics.
Topics: Adult; Azabicyclo Compounds; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypnotic | 1983 |
Zopiclone to geriatric patients. A parallel double-blind dose-response clinical trial of zopiclone as a hypnotic to geriatric patients - a study in a geriatric hospital.
Topics: Aged; Azabicyclo Compounds; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind | 1983 |
Comparison of nitrazepam and zopiclone in psychiatric patients.
Topics: Adolescent; Adult; Aged; Azabicyclo Compounds; Clinical Trials as Topic; Double-Blind Method; Female | 1983 |
Polygraphical sleep recordings in insomniac patients under zopiclone or nitrazepam.
Topics: Adult; Azabicyclo Compounds; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Male; Mid | 1983 |
A comparative study of zopiclone and flunitrazepam in insomniacs seen by general practitioners.
Topics: Adolescent; Adult; Azabicyclo Compounds; Clinical Trials as Topic; Double-Blind Method; Family Pract | 1982 |
Zopiclone to geriatric patients. A parallel double-blind dose-response clinical trial of zopiclone as a hypnotic to geriatric patients - a study in a geriatric hospital.
Topics: Aged; Azabicyclo Compounds; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind | 1982 |
Comparative study of zopiclone and pentobarbitone as hypnotics.
Topics: Adult; Azabicyclo Compounds; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypnotic | 1982 |
A dose-response study in situational insomnia with zopiclone, a new tranquilizer.
Topics: Adolescent; Adult; Analysis of Variance; Azabicyclo Compounds; Clinical Trials as Topic; Dose-Respon | 1980 |
Polygraphical sleep recordings in insomniac patients under zopiclone or nitrazepam.
Topics: Adult; Azabicyclo Compounds; Double-Blind Method; Drug Evaluation; Female; Humans; Hypnotics and Sed | 1982 |
ECG activity in the sleep of insomniac patients under the influence of lormetazepam and zopiclone.
Topics: Aged; Anti-Anxiety Agents; Azabicyclo Compounds; Benzodiazepines; Electrocardiography; Female; Heart | 1995 |
Zopiclone improves sleep quality and daytime well-being in insomniac patients: comparison with triazolam, flunitrazepam and placebo.
Topics: Azabicyclo Compounds; Double-Blind Method; Female; Flunitrazepam; Humans; Male; Middle Aged; Piperaz | 1994 |
[The clinical evaluation of the action of Imovane on patients with insomnia].
Topics: Adolescent; Adult; Analysis of Variance; Azabicyclo Compounds; Chronic Disease; Cluster Analysis; Fe | 1994 |
Double-blind comparison of zopiclone and flunitrazepam in elderly insomniacs with special focus on residual effects.
Topics: Aged; Aged, 80 and over; Azabicyclo Compounds; Dose-Response Relationship, Drug; Double-Blind Method | 1995 |
Pharmacotherapy of transient insomnia related to night work.
Topics: Adult; Azabicyclo Compounds; Circadian Rhythm; Drug Administration Schedule; Humans; Hypnotics and S | 1996 |
Multidrug comparison (lorazepam, triazolam, zolpidem, and zopiclone) in situational insomnia: polysomnographic analysis by means of the cyclic alternating pattern.
Topics: Adult; Azabicyclo Compounds; Female; Humans; Hypnotics and Sedatives; Lorazepam; Male; Middle Aged; | 1997 |
A comparison of zopiclone and propiomazine as hypnotics in outpatients: a multicentre, double-blind, randomized, parallel-group comparison of zopiclone and propiomazine in insomniacs.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Azabicyclo Compounds; Double-Blind Method; Fem | 1997 |
Zopiclone in the treatment of insomnia: an open clinical trial.
Topics: Adult; Azabicyclo Compounds; Female; Humans; Hypnotics and Sedatives; Male; Mental Disorders; Middle | 1998 |
Rebound insomnia after hypnotic withdrawal in insomniac outpatients.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anti-Anxiety Agents; Azabicyclo Compounds; Double-Bli | 1998 |
The effects of substituting zopiclone in withdrawal from chronic use of benzodiazepine hypnotics.
Topics: Adult; Anti-Anxiety Agents; Azabicyclo Compounds; Double-Blind Method; Female; Flunitrazepam; Follow | 1998 |
The effects of zolpidem and zopiclone on daytime sleepiness and psychomotor performance.
Topics: Adult; Azabicyclo Compounds; Cross-Over Studies; Double-Blind Method; Humans; Hypnotics and Sedative | 2000 |
A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects.
Topics: Adult; Azabicyclo Compounds; Dose-Response Relationship, Drug; Double-Blind Method; Electroencephalo | 2001 |
A comparison of efficacy and tolerance of the short acting sedatives midazolam and zopiclone.
Topics: Adolescent; Adult; Azabicyclo Compounds; Double-Blind Method; Female; Humans; Hypnotics and Sedative | 1992 |
Topographical analysis of sleep spindle activity.
Topics: Adult; Aged; Anti-Anxiety Agents; Azabicyclo Compounds; Benzodiazepines; Brain Mapping; Double-Blind | 1992 |
Pattern recognition by matched filtering: an analysis of sleep spindle and K-complex density under the influence of lormetazepam and zopiclone.
Topics: Adult; Aged; Anti-Anxiety Agents; Arousal; Azabicyclo Compounds; Benzodiazepines; Cerebral Cortex; D | 1992 |
[Periodic discharges of sleep spindles with placebo and zopiclone].
Topics: Aged; Azabicyclo Compounds; Cerebral Cortex; Double-Blind Method; Electroencephalography; Evoked Pot | 1992 |
Zopiclone versus flurazepam in insomnia: prolonged administration and withdrawal.
Topics: Adult; Azabicyclo Compounds; Double-Blind Method; Female; Flurazepam; Humans; Hypnotics and Sedative | 1990 |
A dose-range finding study of zopiclone in insomniac patients.
Topics: Adolescent; Adult; Aged; Arousal; Azabicyclo Compounds; Dose-Response Relationship, Drug; Double-Bli | 1990 |
A multi-centre open study in general practice to evaluate the efficacy and acceptability of zopiclone 7.5 mg nocte in patients requiring the prescription of an hypnotic.
Topics: Adult; Aged; Azabicyclo Compounds; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 1990 |
Post marketing surveillance of zopiclone: interim analysis on the first 10,000 cases in a clinical study in general practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arousal; Azabicyclo Compounds; Family Practice; Female; | 1990 |
A comparative study of zopiclone and triazolam in patients with insomnia.
Topics: Adult; Aged; Arousal; Azabicyclo Compounds; Double-Blind Method; Female; Humans; Hypnotics and Sedat | 1990 |
A comparison of the efficacy, safety and withdrawal effects of zopiclone and triazolam in the treatment of insomnia.
Topics: Adolescent; Adult; Azabicyclo Compounds; Double-Blind Method; Female; Humans; Hypnotics and Sedative | 1990 |
Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs.
Topics: Aged; Aged, 80 and over; Arousal; Azabicyclo Compounds; Dose-Response Relationship, Drug; Double-Bli | 1990 |
Zopiclone versus triazolam in insomniac geriatric patients: a specific increase in delta sleep with zopiclone.
Topics: Aged; Aged, 80 and over; Arousal; Azabicyclo Compounds; Delta Rhythm; Double-Blind Method; Electroen | 1990 |
A comparison of the efficacy, tolerance and residual effects of zopiclone, flurazepam and placebo in insomniac outpatients.
Topics: Adolescent; Adult; Arousal; Attention; Azabicyclo Compounds; Body Weight; Double-Blind Method; Drug | 1990 |
A double-blind placebo-controlled trial of zopiclone 7.5 mg and temazepam 20 mg in insomnia.
Topics: Adult; Azabicyclo Compounds; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Malaysia; | 1990 |
Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety.
Topics: Adult; Anxiety Disorders; Azabicyclo Compounds; Drug Administration Schedule; Female; Humans; Hypnot | 1990 |
The influence of age-dependent pharmacokinetics on the pharmacodynamics of hypnotic drugs: comparison of two hypnotics with different half-lives.
Topics: Aged; Arousal; Azabicyclo Compounds; Double-Blind Method; Female; Flurazepam; Half-Life; Hospitaliza | 1989 |
Zopiclone in insomniac shiftworkers. Evaluation of its hypnotic properties and its effects on mood and work performance.
Topics: Adult; Affect; Azabicyclo Compounds; Clinical Trials as Topic; Double-Blind Method; Female; Humans; | 1989 |
Double-blind study on the hypnotic and antianxiety effects of zopiclone compared with nitrazepam in the treatment of insomnia.
Topics: Adult; Anxiety Disorders; Azabicyclo Compounds; Chronic Disease; Clinical Trials as Topic; Double-Bl | 1989 |
Zopiclone: a non-benzodiazepine hypnotic. Controlled comparison to temazepam in insomnia.
Topics: Adult; Aged; Anti-Anxiety Agents; Azabicyclo Compounds; Clinical Trials as Topic; Double-Blind Metho | 1985 |
Insomnia in general practice: the role of temazepam and a comparison with zopiclone.
Topics: Anti-Anxiety Agents; Arousal; Azabicyclo Compounds; Clinical Trials as Topic; Double-Blind Method; H | 1986 |
Subjective effects during administration and on discontinuation of zopiclone and temazepam in normal subjects.
Topics: Adult; Anti-Anxiety Agents; Anxiety; Arousal; Azabicyclo Compounds; Female; Humans; Hypnotics and Se | 1987 |
Zopiclone and nitrazepam: a multicenter placebo controlled comparative study of efficacy and tolerance in insomniac patients in general practice.
Topics: Adult; Aged; Azabicyclo Compounds; Clinical Trials as Topic; Double-Blind Method; Drug Tolerance; Fa | 1987 |
Chronic administration of zopiclone and nitrazepam in the treatment of insomnia.
Topics: Adolescent; Adult; Affect; Aged; Azabicyclo Compounds; Clinical Trials as Topic; Double-Blind Method | 1987 |
Zopiclone versus nitrazepam: a double-blind comparative study of efficacy and tolerance in elderly patients with chronic insomnia.
Topics: Aged; Azabicyclo Compounds; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Drug Tol | 1987 |
Effects of flurazepam and zopiclone on the performance of chronic insomniac patients: a study of ethanol-drug interaction.
Topics: Adult; Azabicyclo Compounds; Drug Interactions; Ethanol; Female; Flurazepam; Humans; Hypnotics and S | 1987 |
Zopiclone: a new nonbenzodiazepine hypnotic used in general practice.
Topics: Adult; Aged; Azabicyclo Compounds; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hy | 1986 |
Comparison of the clinical hypnotic effects of zopiclone and triazolam.
Topics: Adult; Azabicyclo Compounds; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypnotic | 1987 |
Zopiclone in the treatment of insomniacs of family practice.
Topics: Adolescent; Adult; Ambulatory Care; Azabicyclo Compounds; Clinical Trials as Topic; Double-Blind Met | 1985 |
70 other studies available for zopiclone and Chronic Insomnia
| Article | Year |
|---|---|
Clonidine is better than zopiclone for insomnia treatment in chronic pain patients.
Topics: Adult; Azabicyclo Compounds; Chronic Pain; Clonidine; Cross-Over Studies; Humans; Hypnotics and Seda | 2022 |
Assessing sleep-wake survival dynamics in relation to sleep quality in a placebo-controlled pharmacological intervention study with people with insomnia and healthy controls.
Topics: Adult; Aged; Azabicyclo Compounds; Clinical Trials as Topic; Cross-Over Studies; Double-Blind Method | 2021 |
Case report of acute liver injury caused by the eszopiclone in a patient with chronic liver disease.
Topics: Azabicyclo Compounds; Chemical and Drug Induced Liver Injury; Female; Hepatitis B virus; Hepatitis B | 2021 |
Low serum 25-hydroxyvitamin D concentrations in chronic insomnia patients and the association with poor treatment outcome at 2months.
Topics: Adult; Antidepressive Agents; Azabicyclo Compounds; Biomarkers; Case-Control Studies; Chronic Diseas | 2017 |
Delirium associated with only one dose of zopiclone in an older adult.
Topics: Aged, 80 and over; Antioxidants; Azabicyclo Compounds; Delirium; Female; Humans; Hypnotics and Sedat | 2018 |
Insomnia: chasing the dream.
Topics: Animals; Arousal; Azabicyclo Compounds; Azepines; Benzodiazepines; Cognitive Behavioral Therapy; Dox | 2013 |
Benefits and risks of benzodiazepines and Z-drugs: comparison of perceptions of GPs and community pharmacists in Germany.
Topics: Attitude of Health Personnel; Azabicyclo Compounds; Benzodiazepines; Community Pharmacy Services; Fe | 2013 |
Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults.
Topics: Aged; Azabicyclo Compounds; Cognition; Female; Follow-Up Studies; Humans; Hypnotics and Sedatives; M | 2014 |
Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults.
Topics: Aged; Azabicyclo Compounds; Cognition; Female; Follow-Up Studies; Humans; Hypnotics and Sedatives; M | 2014 |
Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults.
Topics: Aged; Azabicyclo Compounds; Cognition; Female; Follow-Up Studies; Humans; Hypnotics and Sedatives; M | 2014 |
Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults.
Topics: Aged; Azabicyclo Compounds; Cognition; Female; Follow-Up Studies; Humans; Hypnotics and Sedatives; M | 2014 |
Misuse of benzodiazepines and Z-drugs in the UK.
Topics: Acetamides; Adolescent; Adult; Anxiety; Azabicyclo Compounds; Benzodiazepines; Female; Humans; Hypno | 2014 |
Correlates of dependence and beliefs about the use of hypnotics among zolpidem and zopiclone users.
Topics: Adult; Azabicyclo Compounds; Depressive Disorder; Diagnosis, Dual (Psychiatry); Female; Hospitals; H | 2015 |
Paradoxical insomnia in a patient taking zopiclone.
Topics: Antidepressive Agents; Azabicyclo Compounds; Citalopram; Deprescriptions; Depressive Disorder, Major | 2017 |
Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines.
Topics: Antidepressive Agents, Second-Generation; Arrhythmias, Cardiac; Azabicyclo Compounds; Benzodiazepine | 2008 |
Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors.
Topics: Adolescent; Adult; Age Factors; Aged; Azabicyclo Compounds; Benzodiazepines; Databases, Factual; Dru | 2009 |
Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem.
Topics: Adult; Affect; Arousal; Attention; Automobile Driving; Azabicyclo Compounds; Cognition; Cross-Over S | 2009 |
A qualitative investigation of long-term zopiclone use and sleep quality among Vietnam war veterans with PTSD.
Topics: Australia; Azabicyclo Compounds; Cohort Studies; Combat Disorders; Follow-Up Studies; Humans; Hypnot | 2009 |
Sleep and sleep disorders in chronic users of zopiclone and drug-free insomniacs.
Topics: Azabicyclo Compounds; Case-Control Studies; Chronic Disease; Female; Humans; Hypnotics and Sedatives | 2009 |
Effect of hypnotic drugs on body balance and standing steadiness.
Topics: Acetamides; Adult; Aged; Alcohol Drinking; Azabicyclo Compounds; Benzodiazepines; Chronic Disease; D | 2010 |
Insomnia: evidence-based approaches to assessment and management.
Topics: Acetamides; Azabicyclo Compounds; Cognitive Behavioral Therapy; Evidence-Based Medicine; Humans; Hyp | 2011 |
[Comparative evaluation of the hypnotic drugs under conditions of brain injury].
Topics: Animals; Azabicyclo Compounds; Brain Injuries; Hypnotics and Sedatives; Hypoxia; Injections, Intrape | 2012 |
[The use of zopiclone for correction of elevated blood pressure in elderly patients with essential hypertension and insomnia].
Topics: Aged; Azabicyclo Compounds; Female; Humans; Hypertension; Hypnotics and Sedatives; Male; Middle Aged | 2002 |
Excessive use of zopiclone: a case report.
Topics: Aged; Azabicyclo Compounds; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Ove | 2002 |
Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats.
Topics: Acetamides; Administration, Oral; Animals; Azabicyclo Compounds; Cerebral Cortex; Dose-Response Rela | 2004 |
Is Eszopiclone appropriate and effective for the long-term clinical management of chronic insomnia?
Topics: Azabicyclo Compounds; Chronic Disease; Humans; Hypnotics and Sedatives; Long-Term Care; Piperazines; | 2004 |
Hypnotic medication: shed light not heat!
Topics: Azabicyclo Compounds; Chronic Disease; Humans; Hypnotics and Sedatives; Piperazines; Sleep Initiatio | 2004 |
Zopiclone dependence after insomnia related to torticollis.
Topics: Azabicyclo Compounds; Female; Humans; Hypnotics and Sedatives; Middle Aged; Piperazines; Sleep Initi | 2005 |
NICE: The National Institute of Clinical Excellence -- or Eccentricity? Reflections on the Z-drugs as hypnotics.
Topics: Acetamides; Azabicyclo Compounds; Benzodiazepines; Half-Life; Humans; Hypnotics and Sedatives; Piper | 2005 |
NICE review: not nice for patients!
Topics: Acetamides; Azabicyclo Compounds; Benzodiazepines; Half-Life; Humans; Hypnotics and Sedatives; Piper | 2005 |
Making decisions in the absence of high quality clinical evidence: we need to bring some science into the judgement.
Topics: Acetamides; Azabicyclo Compounds; Benzodiazepines; Drug Costs; Humans; Hypnotics and Sedatives; Pipe | 2005 |
Short-term treatment with hypnotic drugs for insomnia: going beyond the evidence.
Topics: Acetamides; Azabicyclo Compounds; Benzodiazepines; Cost-Benefit Analysis; Evidence-Based Medicine; H | 2005 |
A NICE missed opportunity?
Topics: Acetamides; Azabicyclo Compounds; Benzodiazepines; Drug Tolerance; Humans; Hypnotics and Sedatives; | 2005 |
Eszopiclone (Lunesta), a new hypnotic.
Topics: Azabicyclo Compounds; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; | 2005 |
Eszopiclone (Lunesta) for treatment of transient and chronic insomnia.
Topics: Azabicyclo Compounds; Drug Evaluation; Humans; Hypnotics and Sedatives; Piperazines; Sleep Initiatio | 2005 |
Eszopiclone (lunesta) for treatment of insomnia.
Topics: Azabicyclo Compounds; Chronic Disease; Humans; Metabolic Clearance Rate; Patient Education as Topic; | 2005 |
Eszopiclone.
Topics: Adult; Azabicyclo Compounds; Biological Availability; Clinical Trials as Topic; Drug Interactions; H | 2006 |
More on sleeping pills.
Topics: Azabicyclo Compounds; Diphenhydramine; Drug Administration Schedule; Histamine H1 Antagonists; Human | 2005 |
Consultation corner. Are the new sleep aids right for you?
Topics: Acetamides; Azabicyclo Compounds; Humans; Hypnotics and Sedatives; Indenes; Piperazines; Pyridines; | 2006 |
Meds and the restless search for sleep.
Topics: Acetamides; Aged; Azabicyclo Compounds; Humans; Hypnotics and Sedatives; Piperazines; Pyridines; Pyr | 2006 |
Dependence on zopiclone.
Topics: Aged; Azabicyclo Compounds; Female; Humans; Hypnotics and Sedatives; Piperazines; Seizures; Sleep In | 2006 |
A comparison of actigraphy and polysomnography in older adults treated for chronic primary insomnia.
Topics: Aged; Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy | 2006 |
A comparison of actigraphy and polysomnography in older adults treated for chronic primary insomnia.
Topics: Aged; Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy | 2006 |
A comparison of actigraphy and polysomnography in older adults treated for chronic primary insomnia.
Topics: Aged; Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy | 2006 |
A comparison of actigraphy and polysomnography in older adults treated for chronic primary insomnia.
Topics: Aged; Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy | 2006 |
Treatment of chronic insomnia with cognitive behavioral therapy vs zopiclone.
Topics: Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Humans; Hypnotics and Sedatives | 2006 |
Treatment of chronic insomnia with cognitive behavioral therapy vs zopiclone.
Topics: Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Humans; Hypnotics and Sedatives | 2006 |
Commentary on a critique for the Journal of Psychopharmacology: NICE--excellence or eccentricity? Reflections on the z-drugs as hypnotics review.
Topics: Acetamides; Azabicyclo Compounds; Benzodiazepines; Humans; Hypnotics and Sedatives; Piperazines; Pra | 2007 |
Zopiclone intoxication: value of electroencephalography in the emergency room.
Topics: Adult; Azabicyclo Compounds; Brain; Electroencephalography; Humans; Hypnotics and Sedatives; Male; P | 2007 |
Zopiclone: is it a pharmacologic agent for abuse?
Topics: Azabicyclo Compounds; Humans; Hypnotics and Sedatives; Male; Middle Aged; Piperazines; Risk Factors; | 2007 |
[Benzodiazepine-like hypnotics--attitudes and prescription practice among general practitioners].
Topics: Adult; Attitude of Health Personnel; Azabicyclo Compounds; Benzodiazepines; Clinical Competence; Fam | 2008 |
Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam.
Topics: Accidents, Traffic; Adolescent; Adult; Aged; Azabicyclo Compounds; Female; Flunitrazepam; Follow-Up | 2008 |
Magic bullets for insomnia? Patients' use and experiences of newer (Z drugs) versus older (benzodiazepine) hypnotics for sleep problems in primary care.
Topics: Acetamides; Adolescent; Adult; Aged; Aged, 80 and over; Attitude to Health; Azabicyclo Compounds; Be | 2008 |
Zopiclone, a third generation of hypnotics. Proceedings of a symposium of the 13th CINP (Collegium Internationale Neuropsychopharmacologicum) congress, Jerusalem, June 1982.
Topics: Azabicyclo Compounds; Humans; Hypnotics and Sedatives; Piperazines; Sleep Initiation and Maintenance | 1982 |
Effects of zopiclone as compared to flurazepam on sleep in women over 40 years of age.
Topics: Azabicyclo Compounds; Double-Blind Method; Drug Evaluation; Electroencephalography; Female; Flurazep | 1982 |
Effects of zopiclone on the sleep of chronic insomniacs.
Topics: Adult; Azabicyclo Compounds; Chronic Disease; Electroencephalography; Female; Humans; Hypnotics and | 1982 |
Efficacy and tolerance of zopiclone in insomniac geriatric patients.
Topics: Aged; Azabicyclo Compounds; Double-Blind Method; Drug Evaluation; Female; Flurazepam; Humans; Hypnot | 1982 |
A postmarketing surveillance study of zopiclone in insomnia.
Topics: Adult; Azabicyclo Compounds; Dreams; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Neu | 1994 |
Amnestic syndrome induced by zoplclone.
Topics: Amnesia; Azabicyclo Compounds; Humans; Hypnotics and Sedatives; Male; Middle Aged; Piperazines; Slee | 1996 |
[The effect of Imovane on sleep structure and respiratory indices during sleep in insomnia patients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azabicyclo Compounds; Chronic Disease; Drug Evaluation; | 1997 |
[Zopiclone dependence. Report of one case].
Topics: Azabicyclo Compounds; Female; Humans; Hypnotics and Sedatives; Middle Aged; Piperazines; Sleep Initi | 1997 |
Health-related quality of life in patients with insomnia treated with zopiclone.
Topics: Azabicyclo Compounds; Clinical Trials as Topic; Humans; Hypnotics and Sedatives; Piperazines; Qualit | 1996 |
Zopiclone use during pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Azabicyclo Compounds; Female; Humans; Hypnotics and Sedatives; P | 2000 |
Treatment of primary insomnia.
Topics: Anti-Anxiety Agents; Azabicyclo Compounds; Benzodiazepines; Humans; Hypnotics and Sedatives; Piperaz | 2000 |
[Observations on use of modern hypnotics. More rapid sleep onset, more frequent uninterrupted sleep and sleep duration].
Topics: Azabicyclo Compounds; Family Practice; Humans; Hypnotics and Sedatives; Piperazines; Sleep Initiatio | 2001 |
[Effectiveness of zopiclone in disorders of initiating and maintaining sleep. Results of a drug monitoring study in 811 general practices].
Topics: Adult; Aged; Azabicyclo Compounds; Data Interpretation, Statistical; Drug Monitoring; Family Practic | 2001 |
[Sleeping poorly due to sedatives (rebound insomnia) and the role of zopiclone].
Topics: Azabicyclo Compounds; Humans; Hypnotics and Sedatives; Piperazines; Sleep Initiation and Maintenance | 1992 |
Postmarketing surveillance of zopiclone in insomnia: analysis of 20,513 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azabicyclo Compounds; Female; Humans; Hypnotics and Seda | 1991 |
Zopiclone.
Topics: Azabicyclo Compounds; Humans; Hypnotics and Sedatives; Piperazines; Sleep; Sleep Initiation and Main | 1990 |
Zopiclone.
Topics: Azabicyclo Compounds; Humans; Piperazines; Product Surveillance, Postmarketing; Sleep Initiation and | 1990 |
Long term efficacy and withdrawal of zopiclone: a sleep laboratory study.
Topics: Adult; Arousal; Azabicyclo Compounds; Electroencephalography; Female; Humans; Hypnotics and Sedative | 1990 |
Zopiclone (Imovane): evaluation in general practice.
Topics: Adolescent; Adult; Aged; Azabicyclo Compounds; Drug Evaluation; Family Practice; Female; Humans; Hyp | 1990 |
Zopiclone in clinical practice.
Topics: Azabicyclo Compounds; Humans; Hypnotics and Sedatives; Piperazines; Sleep Initiation and Maintenance | 1990 |
Zopiclone discontinuation: review of 25 studies assessing withdrawal and rebound phenomena.
Topics: Azabicyclo Compounds; Dose-Response Relationship, Drug; Electroencephalography; Female; Humans; Hypn | 1990 |
A sleep laboratory evaluation of the long-term efficacy of zopiclone.
Topics: Adult; Azabicyclo Compounds; Drug Evaluation; Humans; Hypnotics and Sedatives; Middle Aged; Piperazi | 1988 |
Zopiclone and sleep research.
Topics: Azabicyclo Compounds; Humans; Hypnotics and Sedatives; Piperazines; Sleep; Sleep Initiation and Main | 1987 |